Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
199.03
+2.58 (1.31%)
Nov 5, 2025, 1:44 PM EST - Market open
Natera Revenue
Natera had revenue of $546.60M in the quarter ending June 30, 2025, with 32.24% growth. This brings the company's revenue in the last twelve months to $1.96B, up 44.38% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$1.96B
Revenue Growth
+44.38%
P/S Ratio
13.16
Revenue / Employee
$442,997
Employees
4,434
Market Cap
27.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NTRA News
- 5 days ago - Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT - Business Wire
- 6 days ago - Natera to Report its Third Quarter Results on November 6, 2025 - Business Wire
- 8 days ago - Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity - Business Wire
- 9 days ago - Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 12 days ago - Natera, Inc. (NTRA) Discusses Findings from ESMO Congress Transcript - Seeking Alpha
- 16 days ago - Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients - Business Wire
- 20 days ago - Natera Named to Fast Company's Next Big Things in Tech List - Business Wire
- 23 days ago - Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings - Business Wire